Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Achillion Pharmaceut (ACHN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 406,464
  • Shares Outstanding, K 138,725
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,270 K
  • 60-Month Beta 2.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.67 +7.49%
on 05/03/19
3.25 -11.69%
on 05/17/19
-0.06 (-2.05%)
since 04/18/19
3-Month
2.36 +21.61%
on 02/22/19
3.48 -17.53%
on 04/03/19
+0.40 (+16.19%)
since 02/21/19
52-Week
1.29 +122.48%
on 12/20/18
3.98 -27.89%
on 10/03/18
-0.79 (-21.58%)
since 05/21/18

Most Recent Stories

More News
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab -

ACHN : 2.87 (-2.05%)
Achillion Granted Twentieth Patent for Factor D Portfolio

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today...

ACHN : 2.87 (-2.05%)
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1

Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

ANIK : 37.69 (+1.37%)
ACHN : 2.87 (-2.05%)
BTX : 1.13 (unch)
ALXN : 128.80 (+1.23%)
Achillion: 1Q Earnings Snapshot

NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Thursday reported a loss of $19 million in its first quarter.

ACHN : 2.87 (-2.05%)
Achillion Reports First Quarter 2019 Financial Results

- PNH combo Phase 2 trial interim data to be presented May 17, 2019 -

ACHN : 2.87 (-2.05%)
Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report?

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACHN : 2.87 (-2.05%)
Achillion Meets Enrollment Target in Kidney Disease Studies

Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.

ACHN : 2.87 (-2.05%)
IONS : 69.24 (+2.64%)
NVS : 82.39 (+0.46%)
ALXN : 128.80 (+1.23%)
Report: Developing Opportunities within Mattel, Achillion Pharmaceuticals, Celgene, Adesto Technologies, New Residential Investment, and Entegris -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Mattel, Inc. (NASDAQ:MAT), Achillion...

MAT : 11.01 (+0.46%)
CELG : 96.25 (+1.50%)
ACHN : 2.87 (-2.05%)
IOTS : 7.26 (+1.97%)
NRZ : 16.60 (+0.42%)
ENTG : 36.28 (+0.36%)
CELGZ : 0.70 (-2.44%)
Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy

- Enrolled 23 patients in ACH-4471 Phase 2 C3G six and 12-month clinical trials -

ACHN : 2.87 (-2.05%)
SmarTrend Watching for Potential Pullback in Shares of Achillion Pharma After 2.95% Gain

Achillion Pharma (NASDAQ:ACHN) traded in a range yesterday that spanned from a low of $3.13 to a high of $3.16. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of...

ACHN : 2.87 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ACHN with:

Business Summary

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused...

See More

Key Turning Points

2nd Resistance Point 3.02
1st Resistance Point 2.95
Last Price 2.87
1st Support Level 2.83
2nd Support Level 2.78

See More

52-Week High 3.98
Fibonacci 61.8% 2.95
Last Price 2.87
Fibonacci 50% 2.63
Fibonacci 38.2% 2.32
52-Week Low 1.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar